Market Overview

UPDATE: BMO Capital Downgrades Pfizer

Share:
Related PFE
Pfizer And Western Oncolytics Reach Immuno-Oncology Research Collaboration
18 Biggest Mid-Day Gainers For Wednesday
Biotech Forum Daily Digest: Biotech Tries To Break Through Upward Resistance Levels (Seeking Alpha)

In a report released Monday, BMO Capital analyst Alex Arfaei downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform while reducing its price target from $34 to $31.

Analysts at BMO stated Pfizer has "limited growth prospects." Pfizer's new drug releases do not outweigh its mature franchises heavily declining dividend; backpacks create some short-term support, but not enough for growth maintenance.

Latest Ratings for PFE

DateFirmActionFromTo
Jul 2016JefferiesMaintainsBuy
Jun 2016JefferiesMaintainsBuy
Jun 2016JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Alex Arfaei BMO CapitalDowngrades Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!